21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.

2a ), there remained a highly significant benefit from chemotherapy in the RS group with RS ≥ 31 (HR = 0.18; 95% CI: 0.07–0.47; P < 0.001, Fig. 2d ) with Kaplan–Meier estimates of the proportion of patients distant recurrence-free at 10 years at 56.7% (95% CI: 47.2–66.2) in the patients treated with tamoxifen compared to 89.6% (85.9–93.3%) with the addition of chemotherapy.

also in 132,142 other papers